Guideline Recommendations for Postnatal Glucocorticoid Use in Preterm Infants
Dose Recommendations
- High‑dose dexamethasone (≥ 0.5 mg/kg/day) should never be used in preterm infants because it causes severe neurodevelopmental injury—including cerebral palsy, lower IQ, and hippocampal neuronal degeneration—without providing additional respiratory benefit. 1
- When dexamethasone is unavoidable, limit the dose to 0.1–0.2 mg/kg/day (approximately 0.2 mg/kg/day) to minimize neurodevelopmental risk. 2
- The American Academy of Pediatrics advises using the lowest effective dexamethasone dose (≈ 0.2 mg/kg/day) only when necessary to facilitate extubation and to reduce adverse effects. 3
Timing of Administration
- Avoid any postnatal steroid exposure during the first 7 days of life whenever possible, as early treatment is linked to gastrointestinal perforation—especially when combined with prostaglandin‑synthesis inhibitors. 2
- Reserve postnatal steroid therapy for preterm infants who remain ventilator‑dependent after 7–14 days despite maximal ventilatory and oxygen support. 1
Drug Selection
- First‑line choice for unavoidable glucocorticoid therapy is hydrocortisone (1 mg/kg/day) administered during the first two weeks; it may improve survival without bronchopulmonary dysplasia (particularly in infants exposed to prenatal inflammation) and does not adversely affect neurologic development. 3
- If dexamethasone is required, use the low‑dose regimen (0.1–0.2 mg/kg/day) for the shortest possible duration to aid extubation. [2][3]
- Hydrocortisone has a safer neurodevelopmental profile than dexamethasone when prolonged therapy is needed. 2
Duration and Course
- Limit the course to the minimum necessary: typically 2–3 doses for acute airway indications or 3–7 days for bronchopulmonary dysplasia prevention. 2
Informed Consent and Ethical Considerations
- Obtain informed parental consent, explicitly describing known short‑ and long‑term neurodevelopmental risks such as cerebral palsy and cognitive impairment. 1
Contra‑indications and Pitfalls
- Never use high‑dose regimens (≥ 0.5 mg/kg/day) for any neonatal indication. 2
- Do not confuse dosing strategies for airway management with those for bronchopulmonary dysplasia prevention; they have distinct risk‑benefit profiles. 2
- Routine or prophylactic postnatal steroids to prevent bronchopulmonary dysplasia are not recommended. 1
- Avoid combining dexamethasone and hydrocortisone except in cases of primary adrenal insufficiency, as this only adds to total glucocorticoid exposure without benefit. 4
Long‑Term Outcomes
- High‑dose dexamethasone is associated with persistent neurodevelopmental impairment observed at 4–11 years of age (36 % impairment vs 14 % in placebo). 2
All statements are based on cited evidence; where multiple sources reported the same fact, the non‑Praxis citation was prioritized.